ATRA does not kill malignant cells directly, but returns APL cells to terminal differentiation and stimulates the degradation of abnormal PML/RARα fusion proteins through proteolytic mechanisms [7,8]. The gene discussed is PML; the disease is acute promyelocytic leukemia.